Pharmacy benefit managers are at the forefront of implementing innovative contracting techniques that better align the cost of medications with their value. By offering additional tools to manage specialty drugs, including the use of specialty pharmacies, PBMs and payers are improving the quality and continuity of care patients receive, while ensuring they derive the greatest value from their medications. Over the next 10 years, PBMs and specialty pharmacies will save an estimated total of $654 billion on drug costs for health plan sponsors.
The PCMA PBM Policy Forum is designed for policy makers and staff from Capitol Hill and the Administration, as well as healthcare and drug industry advocates from think tanks, patient advocacy groups, and industry trade associations. The PCMA Policy Forum 2016 hosted almost 200 people from more than 100 companies, organizations, and government offices.
Video Highlights
The FDA’s Role in Promoting Competition
Alex Brill, Chief Executive Officer, Matrix Global Advisors
PBMs’ Role in Clinical Patient Care
William Fleming, President, Healthcare Services, Humana Inc. & Surya Singh, Corporate Vice President & Chief Medical Officer, CVS/Specialty, CVS Health
PCMA Leadership Addresses PBM Industry Solutions for High Price Drugs
Mark Merritt, President & Chief Executive Officer, PCMA
PCMA Leadership Discuss Policy Solutions for High Price Drugs
Mark Merritt, President & Chief Executive Officer, PCMA & William Fleming, President, Healthcare Services, Humana Inc.
PBM Policy Forum 2017 Agenda
| 11:30 am - 12:30 pm | Lunch Reception | |
| 12:30 pm - 1:00 pm | Welcome and Introductions Event Moderator: Susan Dentzer, President & Chief Executive Officer, Network for Excellence in Health Innovation
How PBMs are Part of the Solution in the Drug Price Debate Mark Merritt, President & Chief Executive Officer, PCMA
| |
| 1:00 pm - 1:30 pm | Leveraging PBM Tools to Help Physicians Improve Health William Fleming, Segment President, Healthcare Services, Humana Inc.
| |
| 1:30 pm - 2:00 pm | Competition and the Price of Prescription Drugs Dan Gilman, Attorney Advisor, Federal Trade Commission, Office of Policy Planning
| |
| 2:00 pm - 2:30 pm | PBM Clinical Programs Help to Improve Quality and Lower Costs Surya Singh, Corporate Vice President & Chief Medical Officer, CVS/Specialty, CVS Health
| |
| 2:30 pm - 3:00 pm | The FDA’s Role in Promoting Competition Alex Brill, Chief Executive Officer, Matrix Global Advisors & Research Fellow, American Enterprise Institute
| |
| 3:00 pm - 3:30 pm | Successes in Value Based Contracting Amy Bricker, Vice President, Supply Chain Product and Strategy, Express Scripts
| |
| 3:30 pm - 4:00 pm | Perspectives from HHS Mary Sumpter Lapinski, Special Advisor to the Secretary, U.S. Department of Health and Human Services
| |
| 4:00 pm - 4:30 pm | MedPAC Perspectives on Improving Medicare Part D Mark Miller, Executive Director, Medicare Payment Advisory Commission |
